Long-term Visual and Refractive Outcomes of Argon Laser-treated Retinopathy of Prematurity
Purpose: In this case–control study, we measured visual acuity, objective refraction, ocular biometric parameters, and strabismus in premature cases classified according to the following categories: argon laser-treated retinopathy of prematurity (ROP), untreated spontaneously regressed ROP, no ROP, and full term controls.
Methods: Cases with a history of prematurity at six years of age were categorized into the following groups: patients with a history of treated type 1 ROP using argon laser (group I), untreated spontaneously regressed ROP (group II), and no history of ROP (group III). Group IV included age-matched healthy full-term controls. Funduscopy was performed for all the cases and the control group.
Results: In total, 24 eyes of 12 laser-treated ROP cases, 186 eyes of 93 spontaneously regressed ROP patients, 74 eyes of 37 premature cases with no history of ROP, and 286 eyes of 143 controls were included in the study. The mean spherical equivalent in the treated cases was not significantly different from that in the untreated cases and patients in group III. However, the average cylindrical power was significantly different among the groups (P < 0.004). Furthermore, anisometropia (≥1.5 diopter) was diagnosed with a higher rate in the treated cases (P = 0.03). The corneal curvature of the laser-treated eyes was significantly steeper and the axial length was significantly shorter than those in the other groups (P < 0.002 and P < 0.001, respectively, for multivariate analysis). Strabismus was found in three treated patients (25%). Additionally, there were three treated eyes (12.5%) diagnosed with macular dragging.
Conclusion: Premature cases including those who had a history of argon laser-treated ROP and those with untreated spontaneously regressed ROP showed acceptable long-term visual and refractive outcomes along with a fairly low rate of ocular disorders.
Argon Laser, Ocular Biometric Parameters, Refraction, Retinopathy of Prematurity
1. Ruan L, Shan HD, Liu XZ, Huang X. Refractive status of Chinese with laser-treated retinopathy of prematurity. Optom Vis Sci 2015;92:S3–S9.
2. Azami M, Jaafari Z, Rahmati S, Farahani AD, Badfar G. Prevalence and risk factors of retinopathy of prematurity in Iran: A systematic review and meta-analysis. BMC Ophthalmol 2018;18:83.
3. Yang CS, Wang AG, Sung CS, Hsu WM, Lee FL, Lee SM. Long-term visual outcomes of laser-treated threshold retinopathy of prematurity: A study of refractive status at 7 years. Eye 2010;24:14–20.
4. Heidary F, Gharebaghi R. Outcomes of retinopathy of prematurity. Med Hypothesis Discov Innov Ophthalmol 2016; 5:112–114.
5. Kulkarni S, Shah M, Dole K, Taras S, Deshpande R, Deshpande M. Ocular outcomes and comorbidities in preterm infants enrolled for retinopathy of prematurity screening: A cohort study from western India. Oman J Ophthalmol 2019;12:10–14.
6. Ng EY, Connolly BP, McNamara JA, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: Part 1. Visual function and structural outcome. Ophthalmology 2002;109:928–934.
7. Ospina LH, Lyons CJ, Matsuba C, Jan J, McCormick AQ. Argon laser photocoagulation for retinopathy of prematurity: Long-term outcome. Eye 2005;19:1213–1218.
8. Wu WC, Lin RI, Shih CP, Wang NK, Chen YP, Chao AN, et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology 2012;119:1907–1916.
9. Group EtfRoPC. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684.
10. Talebnejad MR, Nowroozzadeh MH, Mahdaviazad H, Khalili MR, Masoumpour MB, Keshtkar M, et al. The Shiraz pediatric eye study; a population based survey of school age children: Rationale, design and baseline characteristics. J Ophthalmic Vis Res 2018;13:293–300.
11. Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: Ophthalmological outcomes at 10 years. Arch Ophthalmol 2001;119:1110–1118.
12. Connolly BP, Ng EY, McNamara JA, Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: Part 2. Refractive outcome. Ophthalmology 2002;109:936–941.
13. Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol 2013;91:e276–e82.
14. Nguyen PH, Catt C, Nguyen TX, Pham VT. Refractive outcome of prethreshold retinopathy of prematurity treated by diode laser: Follow-up at 5 years. Clin Ophthalmol 2015;9:1753–1758.
15. McLoone EM, O’Keefe M, McLoone SF, Lanigan BM. Longterm refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS 2006;10:454–459.
16. Al-Otaibi AG, Aldrees SS, Mousa AA. Long term visual outcomes in laser treated threshold retinopathy of prematurity in Central Saudi Arabia. Saudi J Ophthalmol 2012;26:299–303.
17. Yang CS, Wang AG, Shih YF, Hsu WM. Astigmatism and biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Eye 2013;27:374–381.
18. Kaur S, Sukhija J, Katoch D, Sharma M, Samanta R, Dogra MR. Refractive and ocular biometric profile of children with a history of laser treatment for retinopathy of prematurity. Indian J Ophthalmol 2017;65:835–840.